Outlook Therapeutics, Inc.

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

• Identityunclaimed
  Published
• Evidencesource_reported
  Published
• Evaluationnot_evaluated
  Published
• MonitoringNot yet published for this record.
  Not published
• AuthorityNot yet published for this record.
  Not published
• Freshnesscurrent
  Published

10 directors published. 8 of 10 with a published determination are independent.

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

• Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
• OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
• FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
• CompensationNot reviewed. Pay design shows how incentives are governed.
• GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
• Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
• AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
• LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
• RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
• CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
• AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
• Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
• Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
• Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
• Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
• Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
• This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

• LA
  Lawrence A. KenyonExecutive Vice President, Chief Financial Officer, Treasurer, Corporate Secretary and Director
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:15, company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:11
• RC
  Robert C. JahrPresident and Chief Executive Officer; Director
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:16, company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:13
• AY
  Amy (Yin-Zhen) HuangDirector
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:5
• FG
  Faisal G. SukhtianDirector
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:6
• GA
  Gerd AuffarthDirector
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:7
• JA
  Julia A. HallerDirector
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:8
• JG
  Julian GangolliDirector
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:9
• KJ
  Kurt J. HilzingerDirector
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:10
• RH
  Ralph H. Randy ThurmanDirector
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:12
• YH
  Yezan HaddadinDirector
  company:f8888e5b-ef4b-40c6-a8fa-e112334a27c0:leadership_role:14

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis

Published company record built from public sources

Sources

5 evidence records cited. 0 with redistribution rights.

Never published

Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry

Record claimed

No

Open disputes

0

Identity ownership

unclaimed

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

1. E1
   Alpha canonical company public projection

   Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
   Open web
   Rights not recorded, link only
   Evidence not pinned
2. E2
   Outlook Therapeutics, Inc. DEF 14A 2026-01-26

   sec proxy. Published Jan 26, 2026. Retrieved Apr 25, 2026. Cited by 10 Claims.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
3. E3
   OTLK DEF 14A executive officers

   sec filing. Published Jan 26, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
4. E4
   OTLK DEF 14A executive officers

   sec filing. Published Jan 26, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
5. E5
   Audit

   board_seats. board seats. Cited by 12 Claims.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned

• Lawrence A. Kenyon executive of Outlook Therapeutics, Inc., effective 2026-01-26.
• Robert C. Jahr executive of Outlook Therapeutics, Inc., effective 2026-01-26.
• Robert C. Jahr seat on Outlook Therapeutics, Inc., effective 2025-01-01.
• Julia A. Haller seat on Outlook Therapeutics, Inc., effective 2022-01-01.
• Amy (Yin-Zhen) Huang seat on Outlook Therapeutics, Inc., effective 2020-01-01.
• Gerd Auffarth seat on Outlook Therapeutics, Inc., effective 2020-01-01.
• Julian Gangolli seat on Outlook Therapeutics, Inc., effective 2020-01-01.
• Julian Gangolli member of Audit, effective 2020-01-01.
• Gerd Auffarth member of Nominating and Governance, effective 2020-01-01.
• Ralph H. Randy Thurman seat on Outlook Therapeutics, Inc., effective 2018-01-01.
• Audit; Compensation · Chair committee of Outlook Therapeutics, Inc., effective 2018-01-01.
• Ralph H. Randy Thurman member of Audit; Compensation · Chair, effective 2018-01-01.
• Faisal G. Sukhtian seat on Outlook Therapeutics, Inc., effective 2017-01-01.
• Yezan Haddadin seat on Outlook Therapeutics, Inc., effective 2017-01-01.
• Nominating and Governance · Chair committee of Outlook Therapeutics, Inc., effective 2017-01-01.
• Faisal G. Sukhtian member of Nominating and Governance · Chair, effective 2017-01-01.
• Kurt J. Hilzinger seat on Outlook Therapeutics, Inc., effective 2015-01-01.
• Lawrence A. Kenyon seat on Outlook Therapeutics, Inc., effective 2015-01-01.
• Audit · Chair; Compensation committee of Outlook Therapeutics, Inc., effective 2015-01-01.
• Kurt J. Hilzinger member of Audit · Chair; Compensation, effective 2015-01-01.